Source comparison
MK-677 for Recovery: Recovery Type Comparison
Muscle Soreness & Damage (DOMS) IGF-1 activates satellite cells; reduces CK and myoglobin release; accelerates myofibril repair 24–48 hours faster return to baseline strength Moderate (RCTs in trained athletes show 30–35% faster CK clearance) MK-677 shortens a
This comparison does not assign a generated winner or score.
- Muscle Soreness & Damage (DOMS)
- IGF-1 activates satellite cells; reduces CK and myoglobin release; accelerates myofibril repair
- 24–48 hours faster return to baseline strength
- Moderate (RCTs in trained athletes show 30–35% faster CK clearance)
- MK-677 shortens acute recovery windows measurably but requires caloric and protein sufficiency to manifest
- Tendon/Ligament Injury
- Upregulates collagen type I and III synthesis; increases fibroblast proliferation; enhances cross-linking
- 8–12 weeks for structural changes visible on imaging
- Low to Moderate (animal models strong; human biopsy data limited)
- Promising for chronic overuse injuries but requires extended protocols; effects are structural, not analgesic
- Sleep Quality & Architecture
- Extends SWS and REM duration via orexin modulation; consolidates sleep cycles
- 3–7 days for subjective improvement; 2–4 weeks for polysomnography changes
- High (multiple crossover trials in elderly and young adults)
- Among the most reliable effects; sleep consolidation alone can improve perceived recovery independent of anabolic signaling
- Post-Surgical or Trauma Recovery
- Systemic IGF-1 elevation supports wound healing, immune function, and nitrogen retention
- 4–8 weeks for measurable lean mass preservation
- Moderate (clinical trials in hip fracture and burn patients show benefit)
- Best used as adjunct to standard rehab; metabolic monitoring essential in surgical populations with insulin resistance
- Neurological Recovery (Concussion, TBI)
- IGF-1 crosses blood-brain barrier; supports neuroplasticity, synaptic repair, and BDNF expression
- 6–12 weeks; difficult to isolate from natural recovery trajectory
- Low (preclinical models only; no human TBI trials published)
- Mechanistically plausible but lacks clinical validation; should not replace standard concussion protocols